See All Slides - tctmd.com

Slides

Presentation TCT 2012

The RealView Holographic Imaging System for Adult Congenital, Structural, and Valvular Heart Disease

Presenter: Elchanan Bruckheimer

October 22, 2012

Presentation TCT 2012

ASD Closure: The European Perspectives

Presenter: Horst Sievert

October 22, 2012

Presentation TCT 2012

Endpoint Selection: Focus on STEMI

Presenter: Stephen Ellis

October 22, 2012

Presentation TCT 2012

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Presenter: Harvey White

October 22, 2012

Presentation TCT 2012

Perivascular MAPCs: Long Term Follow Up and Next Steps

Presenter: Warren Sherman

October 22, 2012

Presentation TCT 2012

Frequency and Management of Left Main Restenosis

Presenter: Bernhard Reimers

October 22, 2012

Presentation TCT 2012

Left Main PCI in the United States: Report from the NCDR

Presenter: J. Matthew Brennan

October 22, 2012

Presentation TCT 2012

Case Presentation (with Discussion): Complex Multivessel Intervention with FFR and IVUS

Presenter: Bon-Kwon Koo

October 22, 2012

Presentation TCT 2012

Frequency, Predictors, and Consequences of Major Vascular Complications After TAVR

Presenter: Philippe Genereux

October 22, 2012

Presentation TCT 2012

The Importance of Frailty Assessments in TAVR Patient Selection: Phenotype Description, Measurement Tools, and Impact on Clinical Outcomes

Presenter: Philip Green

October 22, 2012

Advertisement

Slides

The RealView Holographic Imaging System for Adult Congenital, Structural, and Valvular Heart Disease

ASD Closure: The European Perspectives

Endpoint Selection: Focus on STEMI

When Triple Therapy Is Needed: Warfarin, Dabigatran, Rivaroxaban, and Cilostazol Considerations

Perivascular MAPCs: Long Term Follow Up and Next Steps

Frequency and Management of Left Main Restenosis

Left Main PCI in the United States: Report from the NCDR

Case Presentation (with Discussion): Complex Multivessel Intervention with FFR and IVUS

Frequency, Predictors, and Consequences of Major Vascular Complications After TAVR

The Importance of Frailty Assessments in TAVR Patient Selection: Phenotype Description, Measurement Tools, and Impact on Clinical Outcomes

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content